Chinese herbal medicine for drug-induced liver injury in patients with HIV/AIDS: A systematic review of randomized controlled trials.

Autor:	Zhang XW; Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China., Li J; Beijing Key Laboratory of the Innovative Development of Functional Staple and the Nutritional Intervention for Chronic Disease, China National Research Institute of Food & Fermentation Industries co,.ltd, Beijing 100015, China., Hou WB; Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China., Jiang Y; School of Chinese Medicine, The Chinese University of Hong Kong, Hongkong 999077, China., Zheng RX; Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China., Xu DH; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100029, China., Shen C; Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China., Robinson N; Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.; Institute of Health and Social Care, London South Bank University, London, UK., Liu JP; Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.; The National Research Center in Complementary and Alternative Medicine (NAFKAM), Department of Community Medicine, Faculty of Health Science, UiT The Arctic University of Norway, Tromsø 9037, Norway.
Jazyk:	angličtina
Zdroj:	Integrative medicine research [Integr Med Res] 2023 Mar; Vol. 12 (1), pp. 100918. Date of Electronic Publication: 2022 Dec 23.
DOI:	10.1016/j.imr.2022.100918
Abstrakt:	Background: To explore the effectiveness and safety of Chinese herbal medicine (CHM) for drug-induced liver injury (DILI) in patients with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Methods: A systematic search was made of eight databases (Pubmed, Cochrane Library, Web of Science, Embase, CNKI, Wanfang, VIP, Sinomed) and two trial registries (WHO ICTRP, ClinicalTrials.gov) from inception to September 2022. The effect size was presented as risk ratio (RR) or mean difference (MD) with their 95% confidence interval (CI). The Cochrane Risk of Bias and Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tools were used for quality appraisal. Results: Ten randomized controlled trials (RCTs) involving 732 participants were included. Comparing CHM alone with routine treatment, the CHM group showed lower aspartate aminotransferase (MD=-11.47 U/L, 95%CI[-13.05, -9.89], low certainty), lower alanine aminotransferase (MD=-2.68 U/L, 95%CI[-4.27, -1.08], low certainty), lower total bilirubin (MD=-4.31 mmol/L, 95%CI[-5.66, -2.96], low certainty), lower bilirubin direct (MD=-3.19 mmol/L, 95%CI[-3.87, -2.51], low certainty), and higher effective rate (assessed by symptoms and liver indicators) (RR=1.13, 95%CI[1.06, 1.20], low certainty). A significant difference was also found in CHM plus routine treatment versus routine treatment in the previous outcomes. No significant difference was found on helper T cells among these comparisons. Only one RCT reported safety of CHM and found no adverse reaction during the trial. Conclusions: CHM may improve the liver function indices and effective rate for HIV/AIDS patients with DILI. However, the sample size was small and quality was low. Larger-samples of high-quality trials are needed. (© 2023 Korea Institute of Oriental Medicine. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu